Q-omics provides the consensus-scored PRAMEF11 profile across patient tissues and cancer cell-line models. PRAMEF11 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PRAMEF11 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, PRAMEF11 RNA expression shows 10,736 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, THCA, and COAD as cancer lineages where PRAMEF11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF11 survival associations across molecular data types. PRAMEF11 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF11 RNA expression–survival associations across cancer types. High PRAMEF11 expression shows unfavorable associations in BLCA, CESC, LUAD, ACC, KIRP and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for PRAMEF11 RNA expression.
This table summarizes PRAMEF11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRAMEF11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAMEF11 shows lower tumor expression in THCA and CHOL and higher tumor expression in LIHC. The THCA box plot shows higher PRAMEF11 RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p < 0.001).
This table shows molecular features associated with PRAMEF11 in patient tissues and cancer cell lines. In patient samples, PRAMEF11 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
